Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Intellia Therapeutics (NTLA) has 3 years of Equity Income data on file, last reported at -$4.7 million in Q4 2023.

• Quarterly Equity Income fell 45.57% year-over-year to -$4.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$4.7 million (up 66.59% YoY) and the FY2023 annual result came in at -$15.6 million, down 41.1% from the prior year.
• Equity Income slipped to -$4.7 million in Q4 2023 per NTLA's latest filing, from -$3.9 million in the prior quarter.
• Across five years, Equity Income topped out at -$1.3 million in Q4 2021 and bottomed at -$4.7 million in Q4 2023.
• The 3-year median for Equity Income is -$3.2 million (2022), against an average of -$3.1 million.
• The widest annual swing landed in 2022, when Equity Income slumped 145.13%; it then decreased 11.04% in 2023.
• Tracing NTLA's Equity Income over 3 years: stood at -$1.3 million in 2021, then tumbled by 145.13% to -$3.2 million in 2022, then tumbled by 45.57% to -$4.7 million in 2023.
• Per Business Quant, the three latest NTLA Equity Income figures stand at -$4.7 million (Q4 2023), -$3.9 million (Q3 2023), and -$4.0 million (Q2 2023).

Peer Comparison